Loading clinical trials...
Loading clinical trials...
An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Conditions
Interventions
Regorafenib (Stivarga, BAY73- 4506)
Locations
11
Turkey (Türkiye)
Ankara, Turkey (Türkiye)
Ankara, Turkey (Türkiye)
Antalya, Turkey (Türkiye)
Balcali/Adana, Turkey (Türkiye)
Bursa, Turkey (Türkiye)
Gaziantep, Turkey (Türkiye)
Start Date
July 24, 2013
Primary Completion Date
April 24, 2015
Completion Date
June 11, 2018
Last Updated
April 22, 2019
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions